Fosun International Ltd cut its stake in Eli Lilly And Co (NYSE:LLY) by 39.4% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,965 shares of the company’s stock after selling 1,280 shares during the period. Fosun International Ltd’s holdings in Eli Lilly And Co were worth $272,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Pacitti Group Inc. acquired a new position in Eli Lilly And Co during the fourth quarter worth approximately $25,000. Stonebridge Financial Planning Group LLC grew its stake in shares of Eli Lilly And Co by 70.0% during the 1st quarter. Stonebridge Financial Planning Group LLC now owns 170 shares of the company’s stock valued at $25,000 after buying an additional 70 shares during the period. Sugarloaf Wealth Management LLC purchased a new stake in shares of Eli Lilly And Co during the 4th quarter valued at $26,000. Truvestments Capital LLC acquired a new stake in shares of Eli Lilly And Co during the 1st quarter worth $27,000. Finally, Solstein Capital LLC purchased a new position in shares of Eli Lilly And Co in the 4th quarter worth $34,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.
Shares of LLY traded down $1.12 during mid-day trading on Friday, reaching $151.16. 2,322,495 shares of the stock traded hands, compared to its average volume of 2,875,585. The stock has a fifty day simple moving average of $152.85 and a 200 day simple moving average of $136.00. Eli Lilly And Co has a 12-month low of $101.36 and a 12-month high of $164.90. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 4.37. The firm has a market cap of $145.65 billion, a price-to-earnings ratio of 24.99, a P/E/G ratio of 1.82 and a beta of 0.25.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a dividend of $0.74 per share. The ex-dividend date of this dividend is Thursday, May 14th. This represents a $2.96 annualized dividend and a dividend yield of 1.96%. Eli Lilly And Co’s dividend payout ratio is presently 49.01%.
Several equities research analysts have commented on the company. Cantor Fitzgerald upped their price target on Eli Lilly And Co from $156.00 to $185.00 and gave the stock an “overweight” rating in a research note on Friday, April 24th. Goldman Sachs Group raised shares of Eli Lilly And Co from a “buy” rating to a “conviction-buy” rating and set a $168.00 target price for the company in a research report on Wednesday, March 11th. Cowen lifted their price target on shares of Eli Lilly And Co from $145.00 to $160.00 and gave the company an “outperform” rating in a research report on Wednesday, April 15th. Barclays assumed coverage on shares of Eli Lilly And Co in a research note on Thursday, February 27th. They set an “overweight” rating for the company. Finally, Mizuho raised their target price on shares of Eli Lilly And Co from $148.00 to $155.00 and gave the company a “buy” rating in a research note on Friday, April 24th. Four equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $158.64.
In related news, SVP Myles O’neill sold 25,000 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $140.15, for a total value of $3,503,750.00. Following the completion of the transaction, the senior vice president now owns 44,773 shares of the company’s stock, valued at $6,274,935.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Stephen F. Fry sold 14,657 shares of the firm’s stock in a transaction that occurred on Monday, March 30th. The shares were sold at an average price of $134.30, for a total value of $1,968,435.10. Following the sale, the senior vice president now owns 110,572 shares of the company’s stock, valued at approximately $14,849,819.60. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 906,320 shares of company stock worth $132,984,238. Corporate insiders own 0.09% of the company’s stock.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Further Reading: What Are Cryptocurrencies?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.